Biomarker combinations to simultaneously evaluate non-alcoholic steatohepatitis and hepatic fibrosis status
US11808772B2 · kind B2 · utility
1Cited by
8References
1Claims
0Family size
Inventors
Key dates
| Filing date | Jul 19, 2018 |
| Grant date | Nov 7, 2023 |
| Priority date | — |
| Expiry date | Jun 12, 2040 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/085
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The invention provides a method of diagnosing Non-Alcoholic Steatohepatitis (NASH) and/or the hepatic fibrosis status of a subject, especially a subject afflicted with Non-alcoholic fatty liver disease (NAFLD) or NASH, based on the level of only three or more particular biomarkers. The invention further provides a kit suitable for performing said method and the use of said method and methods of treating patients diagnosed in accordance with the disclosed methods.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.